Role of Advanced Glycation End Products in Hypertension and Atherosclerosis: Therapeutic Implications

被引:0
|
作者
Sudesh Vasdev
Vicki Gill
Pawan Singal
机构
[1] Memorial University of Newfoundland,Discipline of Medicine, Faculty of Medicine, Room H
[2] University of Manitoba,4310, Health Sciences Centre
来源
关键词
Hypertension; Atherosclerosis; Advanced glycation end products; Insulin resistance; Oxidative stress; Inflammation;
D O I
暂无
中图分类号
学科分类号
摘要
The vascular diseases, hypertension and atherosclerosis, affect millions of individuals worldwide, and account for a large number of deaths globally. A better understanding of the mechanism of these conditions will lead to more specific and effective therapies. Hypertension and atherosclerosis are both characterized by insulin resistance, and we suggest that this plays a major role in their etiology. The cause of insulin resistance is not known, but may be a result of a combination of genetic and lifestyle factors. In insulin resistance, alterations in glucose and lipid metabolism lead to the production of excess aldehydes including glyoxal and methylglyoxal. These aldehydes react non-enzymatically with free amino and sulfhydryl groups of amino acids of proteins to form stable conjugates called advanced glycation end products (AGEs). AGEs act directly, as well as via receptors to alter the function of many intra- and extracellular proteins including antioxidant and metabolic enzymes, calcium channels, lipoproteins, and transcriptional and structural proteins. This results in endothelial dysfunction, inflammation and oxidative stress. All these changes are characteristic of hypertension and atherosclerosis. Human and animal studies have demonstrated that increased AGEs are also associated with these conditions. A pathological role for AGEs is substantiated by studies showing that therapies that attenuate insulin resistance and/or lower AGEs, are effective in decreasing oxidative stress, lowering blood pressure, and attenuating atherosclerotic vascular changes. These interventions include lipoic acid and other antioxidants, AGE breakers or soluble receptors of AGEs, and aldehyde-binding agents like cysteine. Such therapies may offer alternative specific means to treat hypertension and atherosclerosis. An adjunct therapy may be to implement lifestyle changes such as weight reduction, regular exercise, smoking cessation, and increasing dietary intake of fruits and vegetables that also decrease insulin resistance as well as oxidative stress.
引用
收藏
页码:48 / 63
页数:15
相关论文
共 50 条
  • [21] The role of advanced glycation end products in various types of neurodegenerative disease: a therapeutic approach
    Parveen Salahuddin
    Gulam Rabbani
    Rizwan Hasan Khan
    Cellular & Molecular Biology Letters, 2014, 19 : 407 - 437
  • [22] Role of Advanced Glycation End Products in Intervertebral Disc Degeneration: Mechanism and Therapeutic Potential
    Yang, Fengguang
    Zhu, Daxue
    Wang, Zhaoheng
    Ma, Yingping
    Huang, Liangzeng
    Kang, Xuewen
    Ma, Bing
    OXIDATIVE MEDICINE AND CELLULAR LONGEVITY, 2022, 2022
  • [23] Pathologic role of dietary advanced glycation end products in cardiometabolic disorders, and therapeutic intervention
    Yamagishi, Sho-ichi
    Matsui, Takanori
    NUTRITION, 2016, 32 (02) : 157 - 165
  • [24] Role of advanced glycation end products on vascular smooth muscle cells under diabetic atherosclerosis
    Mao, Lin
    Yin, Ruili
    Yang, Longyan
    Zhao, Dong
    FRONTIERS IN ENDOCRINOLOGY, 2022, 13
  • [25] Advanced glycation end-products and arterial stiffness in hypertension
    McNulty, Marie
    Mahmud, Azra
    Feely, John
    AMERICAN JOURNAL OF HYPERTENSION, 2007, 20 (03) : 242 - 247
  • [26] Soluble Receptor for Advanced Glycation End Products: A Novel Biomarker for Psoriasis Severity with Therapeutic Implications?
    Batycka-Baran, Aleksandra
    Baran, Wojciech
    Nowicka-Suszko, Danuta
    Szepietowski, Jacek C.
    ACTA DERMATO-VENEREOLOGICA, 2018, 98 (08) : 797 - 798
  • [27] A Role for Advanced Glycation End Products in Molecular Ageing
    Zgutka, Katarzyna
    Tkacz, Marta
    Tomasiak, Patrycja
    Tarnowski, Maciej
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2023, 24 (12)
  • [28] Role of advanced glycation end products in cardiovascular disease
    Hegab, Zeinab
    Gibbons, Stephen
    Neyses, Ludwig
    Mamas, Mamas A.
    WORLD JOURNAL OF CARDIOLOGY, 2012, 4 (04): : 90 - 102
  • [29] Aging ovary and the role for advanced glycation end products
    Pertynska-Marczewska, Magdalena
    Diamanti-Kandarakis, Evanthia
    MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY, 2017, 24 (03): : 345 - 351
  • [30] Role of advanced glycation end products in diabetic nephropathy
    Forbes, JM
    Cooper, ME
    Oldfield, MD
    Thomas, MC
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2003, 14 : S254 - S258